Anemia

FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia over IS.

A new systematic review finds IV iron effective for iron non-responders but calls for further studies on the causes of oral iron failure.

Anemia was linked to lower waist circumference, lower albumin levels, and treatment regimens in females, but not males.

Iron deficiency was more common in acute versus chronic heart failure, with notable differences in detection by numerous recommended definitions.

The FDA approved an expanded label for avacincaptad pegol, removing limitations on the duration of dosing beyond 12 months.

Meta-analysis suggests iron therapy lowers the risk of heart failure hospitalization and cardiovascular death in patients with chronic kidney disease.

Iron administration was linked to a decrease in platelet counts, even in the absence of preexisting thrombocytosis.

Emblaveo combines aztreonam, a monobactam antibiotic, and avibactam, a β-lactamase inhibitor.

More than 90% of patients with hemophilia B eliminated factor IX prophylaxis 4 years after treatment with etranacogene dezaparvovec (HEMGENIX) gene therapy.

Interim analysis of the Phase 3 FRONTIER3 trial found Mim8 well-tolerated in children with hemophilia A with and without inhibitors.

Axatilimab in 9 mg and 22 mg vial sizes are expected to launch in early February for the treatment of chronic graft-versus-host disease.

2 phase 3 trials show iptacopan improves fatigue, quality of life, and hematologic markers in C5i-experienced or -naive patients with paroxysmal nocturnal hemoglobinuria.

An infusion of ferric carboxymaltose in the third trimester significantly reduced anemia in pregnant women, surpassing the efficacy of iron tablets.

A new study highlights notable obesity-associated disruptions of iron metabolism, with higher hemoglobin and serum ferritin levels in pre-obese and obese cohorts.

Nearly half of patients with acute coronary syndrome in a single-center analysis exhibited iron deficiency, with anemia linked to a greater impact on mortality.

A study found that NT-proBNP levels predict cardiovascular and renal risks in patients with advanced CKD and anemia. Greater NT-proBNP variability showed increased renal risks.

A study shows that a lower non-HDL/HDL cholesterol ratio is linked to greater anemia prevalence. A threshold of 4.28 shows a 15% anemia risk drop per unit increase below this value.

Concizumab marks the first subcutaneous injection treatment for hemophilia A or B with inhibitors, demonstrating an 86% reduction in bleeds in pivotal trial data.

A hematologist discusses the role of internal and family medicine practitioners in improving the diagnosis and management of iron deficiency.

Steven Fein, MD, discusses news and updates in sickle cell disease following ASH 2024.

In this video, a hematologist discusses trials and areas of advancement he is excited about in the current landscape.

In part 2 of our 5-part series, Steven Fein, MD, discusses updates in iron deficiency management from 2024.

In this video, Steven Fein, MD, discusses updates and topics of note from the American Society of Hematology annual meeting.

Yale study at ASH 2024 finds screening adult women for iron deficiency with a ferritin threshold of 25 µg/L is cost-effective.